🔍 Search
Vascular mimicPseudo-KaposiHHV-8 negative

Acroangiodermatitis (pseudo-Kaposi sarcoma)

Pseudo-Kaposi sarcoma; acroangiodermatitis of Mali; Stewart-Bluefarb syndrome; acral capillary angiomatosis; angiodermatitis associated with venous hypertension or AV shunting

Acroangiodermatitis is a reactive angioproliferative dermatosis, usually driven by venous hypertension, arteriovenous shunting or chronic limb dependency. It matters in skin oncology because violaceous plaques and nodules on the lower limbs can look clinically and histologically like Kaposi sarcoma. The safe clinical approach is to identify the vascular driver, biopsy when Kaposi sarcoma or angiosarcoma is plausible, and treat the haemodynamic problem rather than the skin change alone.

CurrentLast reviewed 5 June 2026

Clinical recognition

  • Classically presents with violaceous, red-brown or purpuric papules, plaques or nodules on the feet, ankles or lower legs.
  • Often coexists with chronic venous insufficiency: oedema, varicosities, stasis dermatitis, lipodermatosclerosis, atrophie blanche or ulceration.
  • Unilateral disease should prompt consideration of an arteriovenous malformation, acquired AV fistula or dialysis access-related shunting.
  • Bilateral lower-limb disease is more often associated with venous hypertension and stasis.
  • The oncology problem is mimicry: Kaposi sarcoma, angiosarcoma, vasculitis, pigmented purpura and chronic ulcer-associated SCC may all enter the differential.

Pathophysiology and types

  • The lesion is reactive rather than malignant: chronic venous pressure or AV shunting stimulates dermal capillary proliferation and red-cell extravasation.
  • Mali-type acroangiodermatitis is associated with chronic venous insufficiency and exaggerated stasis change.
  • Stewart-Bluefarb syndrome describes pseudo-Kaposi lesions associated with congenital arteriovenous malformation of the lower limb.
  • Acquired cases may occur around arteriovenous fistulae, including haemodialysis access, or in chronically dependent or paralysed limbs.
  • Persistent inflammation, haemosiderin and fibrosis explain the brown-purple colour and chronicity.

Diagnosis

  • Assess venous disease and pulses clinically; consider duplex ultrasound or vascular referral when venous hypertension, arterial disease or AV shunting is suspected.
  • Biopsy is appropriate if the lesion is atypical, progressive, nodular, ulcerated, solitary, in an immunosuppressed patient or clinically difficult to separate from Kaposi sarcoma or angiosarcoma.
  • Histology usually shows dermal capillary proliferation, red-cell extravasation, haemosiderin and fibrosis without destructive malignant vascular infiltration.
  • HHV-8 / LNA-1 immunostaining is useful when Kaposi sarcoma is in the differential; acroangiodermatitis should be HHV-8 negative.
  • Clinicopathological correlation is essential because superficial vascular change over a chronic ulcer does not exclude a deeper neoplasm if the clinical lesion is suspicious.

Management

  • Treat the haemodynamic driver: compression, elevation and venous-ulcer care are central when arterial supply is adequate.
  • Investigate and manage AV fistulae or AV malformations with vascular services when they are the driver.
  • Topical steroids may help associated stasis dermatitis but do not correct the underlying vascular stimulus.
  • Do not treat a convincing pseudo-Kaposi lesion as Kaposi sarcoma unless histology and HHV-8 testing support that diagnosis.
  • Review persistent ulceration, growth, pain or bleeding promptly because chronic venous disease can coexist with true skin cancer.

Pitfalls

  • Calling all purple lower-leg plaques “stasis” can miss Kaposi sarcoma, angiosarcoma or Marjolin-type SCC.
  • Calling every pseudo-Kaposi-like plaque Kaposi sarcoma can lead to unnecessary cancer staging and treatment.
  • Compression should be used only after confirming adequate arterial inflow according to local vascular practice.
  • A single small biopsy from an ulcer edge may sample only reactive vascular change; re-biopsy is reasonable if the clinical course does not fit.
  • In immunosuppressed or HIV-positive patients, maintain a lower threshold for biopsy and HHV-8 staining.

References

  1. Kanwar AJ et al. Acroangiodermatitis (pseudo-Kaposi sarcoma). Indian Dermatol Online J. 2014.
  2. Nogueira A et al. Acroangiodermatitis: clinical and dermatopathological features. An Bras Dermatol. 2014.
  3. Medscape. Pseudo-Kaposi sarcoma (acroangiodermatitis).

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.